Following the investment, HealthCap will establish a local presence in Copenhagen at the BioInnovation Institute (BII) to increase its focus on Nordic investment opportunities.

“We are proud to welcome two of Denmark’s most respected investors as LPs in HealthCap IX. The investments from Novo Holdings and EIFO not only enhance HealthCap’s ability to support transformative healthcare companies but also reinforce the Nordic region’s position as a global leader in life science innovation and entrepreneurship,” says Mårten Steen, Managing Partner, HealthCap.

Related article

How to pitch to life science VCs

Nordic life science companies are generally of good quality, but can often be better at pitching compared to US-based companies and entrepreneurs. Effective pitching is a skill, and is centered on good storytelling to get an investor’s full attention and buy-in. Since I work for the life science VC, HealthCap, I thought I would share […]


The investments from Novo Holdings and EIFO not only enhance HealthCap’s ability to support transformative healthcare companies but also reinforce the Nordic region’s position as a global leader in life science innovation and entrepreneurship.

In particular, the fund has committed to supporting early-stage companies emerging from academic and corporate research environments, with the aim of helping them progress towards further financing, it states.

This marks EIFO’s first investment with HealthCap, while Novo Holdings has previously backed earlier HealthCap funds.

“We are pleased to continue our collaboration with HealthCap, which over many years has proven to be a strong partner in advancing the next generation of healthcare solutions. With this commitment, we aim to support high-quality scientific projects in the Nordics and ensure they have the support needed to develop into well-structured companies with clinical and commercial success,” says Daniel Rasmussen, Principal, Seed Investments, Novo Holdings.